The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
Open accessAbstract
Human solid tumors frequently have pronounced heterogeneity of both neoplastic and normal cells on the histological, genetic, and gene expression levels. While current efforts are focused on understanding heterotypic interactions between tumor cells and surrounding normal cells, much less is known about the interactions between and among heterogeneous tumor cells within a neoplasm. In glioblastoma multiforme (GBM), epidermal growth factor receptor gene (EGFR) amplification and mutation (EGFRvIII/ΔEGFR) are signature pathogenetic events that are invariably expressed in a heterogeneous manner. Strikingly, despite its greater biological activity than wild-type EGFR (wtEGFR), individual GBM tumors expressing both amplified receptors typically express wtEGFR in far greater abundance than the ΔEGFR lesion. We hypothesized that the minor ΔEGFR-expressing subpopulation enhances tumorigenicity of the entire tumor cell population, and thereby maintains heterogeneity of expression of the two receptor forms in different cells. Using mixtures of glioma cells as well as immortalized murine astrocytes, we demonstrate that a paracrine mechanism driven by ΔEGFR is the primary means for recruiting wtEGFR-expressing cells into accelerated proliferation in vivo. We determined that human glioma tissues, glioma cell lines, glioma stem cells, and immortalized mouse Ink4a/Arf−/−astrocytes that express ΔEGFR each also express IL-6 and/or leukemia inhibitory factor (LIF) cytokines. These cytokines activate gp130, which in turn activates wtEGFR in neighboring cells, leading to enhanced rates of tumor growth. Ablating IL-6, LIF, or gp130 uncouples this cellular cross-talk, and potently attenuates tumor growth enhancement. These findings support the view that a minor tumor cell population can potently drive accelerated growth of the entire tumor mass, and thereby actively maintain tumor cell heterogeneity within a tumor mass. Such interactions between genetically dissimilar cancer cells could provide novel points of therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 2×
“IL-6-type cytokines are well known potent activators of the JAK/STAT3 pathway (Schaefer et al. 2000; Heinrich et al. 2003), the inhibition of which has been shown to promote apoptosis in GBM cells (Rahaman et al. 2002).”
BackgroundMalignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Self-citationIntercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells
Al-Nedawi, K., Meehan, B., Micallef, J., Lhotak, V., May, L., Guha, A., & Rak, J. (2008) · Nature Cell Biology · doi:10.1038/ncb1725 · Cited by 2,034
The WHO classification of tumors of the nervous system
Kleihues, P., Louis, D. N., Scheithauer, B. W., Rorke, L. B., Reifenberger, G., Burger, P. C., & Cavenee, W. K. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.215 · Cited by 1,547
Self-citationMolecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Self-citationMalignant glioma: genetics and biology of a grave matter
Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., & DePinho, R. A. (2001) · Genes & Development · doi:10.1101/gad.891601 · Cited by 1,229
Self-citationA mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
Self-citationPrognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663
Epidermal growth factor receptor and Ink4a/Arf
Bachoo, R. M., Maher, E. A., Ligon, K. L., Sharpless, N. E., Chan, S. S., You, M. J., Tang, Y., DeFrances, J., Stover, E., Weissleder, R., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00046-6 · Cited by 652
Self-citationHuang, H.-J. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X.-D., Huang, C.-M., Gill, G. N., Wiley, H. S., & Cavenee, W. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.5.2927 · Cited by 595
Self-citationHolland, E. C., Hively, W. P., DePinho, R. A., & Varmus, H. E. (1998) · Genes & Development · doi:10.1101/gad.12.23.3675 · Cited by 556
Self-citationPeñuelas, S., Anido, J., Prieto-Sánchez, R. M., Folch, G., Barba, I., Cuartas, I., García-Dorado, D., Poca, M. A., Sahuquillo, J., Baselga, J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.011 · Cited by 526
Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., & Aldape, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1737 · Cited by 516
Trikha, M., Corringham, R. E., Klein, B., & Rossi, J. (2003) · PubMed · Cited by 506
Gschwind, A., Zwick, E., Prenzel, N., Leserer, M., & Ullrich, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204192 · Cited by 462
Nagane, M., Coufal, F. J., Lin, H., Bögler, O., Cavenee, W. K., & Huang, H.-J. S. (1996) · PubMed · Cited by 405
Self-citationHedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
Tian, H., Callahan, C. A., DuPree, K. J., Darbonne, W. C., Ahn, C. P., Scales, S. J., & de Sauvage, F. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813203106 · Cited by 404
Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. B., & White, F. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705158104 · Cited by 390
Self-citationRahaman, S. O., Harbor, P. C., Chernova, O., Barnett, G. H., Vogelbaum, M. A., & Haque, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206047 · Cited by 377
Nagane, M., Levitzki, A., Gazit, A., Cavenee, W. K., & Huang, H.-J. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5724 · Cited by 363
Self-citationOncogenic EGFR Signaling Networks in Glioma
Huang, P. H., Xu, A. M., & White, F. M. (2009) · Science Signaling · doi:10.1126/scisignal.287re6 · Cited by 363
Targeting Interleukin 6 Signaling Suppresses Glioma Stem Cell Survival and Tumor Growth
Wang, H., Lathia, J. D., Wu, Q., Wang, J., Li, Z., Heddleston, J. M., Eyler, C. E., Elderbroom, J., Gallagher, J., Schuschu, J., et al. (2009) · Stem Cells · doi:10.1002/stem.188 · Cited by 333
Wikstrand, C. J., McLendon, R. E., Friedman, A. H., & Bigner, D. D. (1997) · PubMed · Cited by 332
Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone
Yamauchi, T., Ueki, K., Tobe, K., Tamemoto, H., Sekine, N., Wada, M., Honjo, M., Takahashi, M., Takahashi, T., Hirai, H., et al. (1997) · Nature · doi:10.1038/36369 · Cited by 285
Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
Qiu, Y., Ravi, L., & Kung, H.-J. (1998) · Nature · doi:10.1038/30012 · Cited by 280
Rathjen, P. D., Toth, S., Willis, A., Heath, J. K., & Smith, A. G. (1990) · Cell · doi:10.1016/0092-8674(90)90387-t · Cited by 270
Jaros, E., Perry, R., Adam, L., Kelly, P., Crawford, P., Kalbag, R., Mendelow, A., Sengupta, R., & Pearson, A. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.273 · Cited by 264
An implantable guide-screw system for brain tumor studies in small animals
Lal, S., Lacroix, M., Tofilon, P., Fuller, G. N., Sawaya, R., & Lang, F. F. (2000) · Journal of Neurosurgery · doi:10.3171/jns.2000.92.2.0326 · Cited by 244
Brantley, E. C., & Benveniste, E. N. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2180 · Cited by 236
Human glioblastoma cells release interleukin 6 in vivo and in vitro.
Meir, E. G. V., Sawamura, Y., Diserens, A. C., Hamou, M., & de Tribolet, N. (1990) · PubMed · Cited by 235
Leukemia Inhibitory Factor Promotes Neural Stem Cell Self-Renewal in the Adult Brain
Bauer, S., & Patterson, P. H. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3047-06.2006 · Cited by 234
Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis
Zhu, H., Acquaviva, J., Ramachandran, P., Boskovitz, A., Woolfenden, S., Pfannl, R., Bronson, R. T., Chen, J. W., Weissleder, R., Housman, D. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813314106 · Cited by 231
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR
Pandita, A., Aldape, K. D., Zadeh, G., Guha, A., & James, C. D. (2004) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10300 · Cited by 211
Schlegel, J., Merdes, A., Stumm, G., Albert, F. K., Forsting, M., Hynes, N., & Kiessling, M. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560114 · Cited by 201
Amplification of Epidermal Growth Factor Receptor Gene in Gliomas: Histopathology and Prognosis
Hurt, M. R., Moossy, J., Donovan-Peluso, M., & Locker, J. (1992) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199201000-00010 · Cited by 197
IL-6 is required for glioma development in a mouse model
Weissenberger, J., Loeffler, S., Kappeler, A., Kopf, M., Lukes, A., Afanasieva, T. A., Aguzzi, A., & Weis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207455 · Cited by 189
Narita, Y., Nagane, M., Mishima, K., Huang, H.-J. S., Furnari, F. B., & Cavenee, W. K. (2002) · PubMed · Cited by 189
Self-citationPredominant Expression of Mutant EGFR (EGFRvIII) is Rare in Primary Glioblastomas
Biernat, W., Huang, H., Yokoo, H., Kleihues, P., & Ohgaki, H. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00045.x · Cited by 152
Interleukin-6 gene amplification and shortened survival in glioblastoma patients
Tchirkov, A., Khalil, T. A., Chautard, E., Mokhtari, K., Véronèse, L., Irthum, B., Vago, P., Kemeny, J., & Verrelle, P. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603586 · Cited by 140
Ramnarain, D. B., Park, S., Lee, D. Y., Hatanpaa, K. J., Scoggin, S. O., Otu, H., Libermann, T. A., Raisanen, J. M., Ashfaq, R., Wong, E. T., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2753 · Cited by 140
Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma
Nishikawa, R., Sugiyama, T., Narita, Y., Furnari, F. B., Cavenee, W. K., & Matsutani, M. (2004) · Brain Tumor Pathology · doi:10.1007/bf02484510 · Cited by 126
Self-citationInterleukin‐6‐Mediated Autocrine Growth Promotion in Human Glioblastoma Multiforme Cell Line U87MG
Goswami, S. K., Gupta, A., & Sharma, S. K. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71051837.x · Cited by 113
Interleukin-6 overexpression as a marker of malignancy in human gliomas
Rolhion, C., Penault-Llorca, F. M., Kémény, J., Lemaire, J., Jullien, C., Bouvier, C., Finat‐Duclos, F., & Verrelle, P. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.94.1.0097 · Cited by 106
Jung, V., Romeike, B. F. M., Henn, W., Feiden, W., Moringlane, J. R., Zang, K. D., & Urbschat, S. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199909000-00009 · Cited by 104
Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme
Chang, C.-Y., Li, M., Liao, S., Huang, Y.-L., Shen, C., & Pan, H.-C. (2005) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2004.11.017 · Cited by 96
Jeuken, J. W. M., Sijben, A. E. J., Alenda, C., Rijntjes, J., Dekkers, M. M. G., Boots‐Sprenger, S., McLendon, R. E., & Wesseling, P. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00320.x · Cited by 85
Johns, T. G., Perera, R. M., Vernes, S. C., Vitali, A. A., Cao, D. X., Cavenee, W. K., Scott, A. M., & Furnari, F. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1453 · Cited by 84
Self-citationIL-6 gene amplification and expression in human glioblastomas
Tchirkov, A., Rolhion, C., Bertrand, S., Doré, J. F., Dubost, J. J., & Verrelle, P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1942 · Cited by 78
Using Mice to Decipher the Molecular Genetics of Brain Tumors
Hesselager, G., & Holland, E. C. (2003) · Neurosurgery · doi:10.1227/01.neu.0000081304.57547.b5 · Cited by 55
Kudo, M., Jono, H., Shinriki, S., Yano, S., Nakamura, H., Makino, K., Hide, T., Muta, D., Ueda, M., Ota, K., et al. (2009) · Journal of neurosurgery · doi:10.3171/2008.12.jns081284 · Cited by 53
Advances in the biology of astrocytomas
Guha, A., & Mukherjee, J. (2004) · Current Opinion in Neurology · doi:10.1097/00019052-200412000-00004 · Cited by 47
Schaefer, L. K., Menter, D. G., & Schaefer, T. S. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(99)00077-7 · Cited by 43
Multiple Forms of Human Interleukin‐6
May, L. T., Santhanam, U., Tatter, S. B., Ghrayeb, J., & Sehgal, P. B. (1989) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1989.tb24004.x · Cited by 42
Liu, J., Guo, L., Luo, Y., Li, J., & Li, H. (2000) · PubMed · Cited by 37
Adams, T. E., Koziolek, E. J., Hoyne, P. A., Bentley, J. D., Lu, L., Lovrecz, G. O., Ward, C. W., Lee, F.-T., Scott, A. M., Nash, A. D., et al. (2009) · Growth Factors · doi:10.1080/08977190902843565 · Cited by 22
Self-citationA possible growth factor role of IL-6 in neuroectodermal tumours
Candi, E., Knight, R. A., Spinedi, A., Guerrieri, P., & Melino, G. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005706019048 · Cited by 20
Cited by
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Self-citationClonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
“The authors found a paracrine mechanism sustaining growth of the dominant EGFR wild type clones through IL-6 and/or LIF from the EGFRvIII deletion mutants leading to wtEGFR activation in neighboring clones, sustaining tumor heterogeneity (Inda et al., 2010).”
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Wilm, A., Aw, P. P. K., Bertrand, D., Yeo, G. H. T., Ong, S. H., Wong, C. H., Khor, C. C., Petric, R., Hibberd, M. L., & Nagarajan, N. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks918 · Cited by 1,372
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution
McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077
Metadata
- Authors
- Inda, M.-D.-M., Bonavia, R., Mukasa, A., Narita, Y., Sah, D. W. Y., Vandenberg, S., Brennan, C., Johns, T. G., Bachoo, R., Hadwiger, P., Tan, P., DePinho, R. A., Cavenee, W., & Furnari, F.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2010-08-15
- Volume
- 24
- Issue
- 16
- Pages
- 1731-1745
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2102626211
- Cited by
- 543
- References
- 57
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.